Stock Events

Stock Events

Advanced Proteome Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
0Revenue
625,039.64Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Repligen
RGEN
Mkt Cap11.23B
Repligen Corporation is involved in the development and production of materials used in biological drugs, which competes with APTCF's focus on enhancing protein therapeutics.
Illumina
ILMN
Mkt Cap35.63B
Illumina, Inc. provides genomics solutions, including sequencing technologies that are crucial for proteomics research, directly competing with APTCF's proteomic technology applications.
Bio-Techne
TECH
Mkt Cap11.41B
Bio-Techne Corporation manufactures and sells biotechnology products and clinical diagnostic controls which overlap with APTCF's work in protein therapeutics.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a large pharmaceutical company that develops and manufactures healthcare products including protein-based therapies, competing in the same space as APTCF.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. focuses on human therapeutics, including treatments based on advanced protein engineering and modification, similar to APTCF's core activities.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its focus on protein-based therapeutics, directly competing with APTCF in the field of proteome therapeutics.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals Incorporated researches and develops drugs in various fields including those that involve protein therapeutics, competing with APTCF.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. develops and markets drugs that are in direct competition with APTCF's therapeutic protein products.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies which are a subset of protein therapeutics, placing them in competition with APTCF.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk A/S is a global healthcare company that develops protein-based therapies, particularly in the area of diabetes, competing with APTCF's protein enhancement technologies.

About

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.
Show More
CEO
Mr. Kenneth Clifford Phillippe B.Comm, CA, CPA
Country
United States
ISIN
CA0076281009

Listings

MU
DE
0E8.MU
STU
DE
0E81.STU
STU
DE
0E8.STU

0 Comments

Share your thoughts

FAQs

What is Advanced Proteome Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Advanced Proteome Therapeutics stocks are traded under the ticker 0E8.STU.
What is Advanced Proteome Therapeutics revenue for the last year?▼
Advanced Proteome Therapeutics revenue for the last year amounts to 0 EUR.
What is Advanced Proteome Therapeutics net income for the last year?▼
0E8.STU net income for the last year is 625,039.64 EUR.
In which sector is Advanced Proteome Therapeutics located?▼
Advanced Proteome Therapeutics operates in the Health & Wellness sector.
When did Advanced Proteome Therapeutics complete a stock split?▼
The last stock split for Advanced Proteome Therapeutics was on May 8, 2019 with a ratio of 1:10.
Where is Advanced Proteome Therapeutics headquartered?▼
Advanced Proteome Therapeutics is headquartered in Burnaby, United States.